Synektik stock trades at EUR 78.63 ahead of November 18 results

Published on 10/20/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue reached PLN 441.16 million and EBITDA PLN 118.03 million in the first half of 2026. Synektik stock costs EUR 78.63 on October 20, 2026.

Contracts and reporting dates

Synektik signed a PLN 16.14 million da Vinci contract on October 16, 2026.
First-half 2026 revenue reached PLN 441.16 million and EBITDA was PLN 118.03 million.
Synektik stock trades at EUR 78.63 at 12:44 p.m. CEST at Lang & Schwarz on October 20, 2026.

Synektik, PLSNKTK00019, Illustration mit AI erstellt.

Synektik (ISIN PLSNKTK00019) was trading at EUR 78.63 at Lang & Schwarz on October 20, 2026 at 12:44 p.m. CEST, while the company prepares to publish its next quarterly report on November 18, 2026. The Warsaw-listed medical technology group is entering that date with first-half revenue of PLN 441.16 million and EBITDA of PLN 118.03 million, according to Stockd.

Contracts add operating visibility

Synektik's recent contract flow provides the clearest operating context for the November report. On October 16, 2026, the company signed a PLN 16,138,798.89 agreement to deliver and install a da Vinci surgical system for a Krakow hospital. The project includes staff training, adaptation work and warranty service, with delivery due within eight months, according to Bankier.pl.

The contract value exceeds 5 percent of group equity and will contribute to sales in fiscal year 2026, which runs from October 1, 2026, through September 30, 2027. That timing makes revenue conversion and margins more important than the headline contract value alone.

What does the next report add?

The first-half figures show a business with strong operating scale but a reported earnings distortion. Revenue was PLN 441.16 million, EBITDA was PLN 118.03 million and net income was PLN 331.33 million in the first half of 2026. Stockd noted that PLN 261.3 million of the net income came from a one-time, non-cash gain connected with the separation of Syn2bio, while continuing operations generated PLN 82.9 million.

Three recent dates and figures

On October 8, 2026, Synektik signed a PLN 15,006,536.18 contract for da Vinci consumables, as reported by Stockd. On October 14, 2026, a Bankier forum post reported a PLN 1.86 million post-warranty service agreement. On October 16, 2026, the PLN 16.14 million da Vinci system contract was announced.

Reporting dates ahead

Synektik's next consolidated quarterly report is scheduled for November 18, 2026. The separate and consolidated annual reports for fiscal year 2025 are scheduled for December 22, 2026, according to PAP.

Stock valuation context

On the Warsaw Stock Exchange, Synektik's SNT shares were last quoted at PLN 346.40 on October 20, 2026 at 12:36 p.m. CEST. The same market snapshot placed its market capitalization at PLN 3.0 billion and its 52-week range at PLN 236.18 to PLN 398.40. The range leaves the Polish share price below its yearly high while the German euro quotation remains the relevant reference for investors using Lang & Schwarz.

The further course of trading is shown by the continuously updated real-time quote of Synektik stock.